Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM)

Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM)

September 27, 2006

    BEIJING, Sept. 27 /Xinhua-PRNewswire/ -- Sinovac
Biotech Ltd. (AMEX: SVA) announced today that the third
product of the Company, seasonal influenza vaccine, is
successfully released for sale by National Institute for
the Control of Pharmaceutical and Biological Products
("NICPBP").  On the same day, the first bunch of
purchase orders is signed with several customers.  These
purchase orders represent a major step for the Company as
its third vaccine product begins sales in China.  And it is
expected to be another major source to generate sales
revenue for the Company. 

    Sinovac's VP of Marketing and Sales commented, "We
expect Chinese flu vaccine market to bear a high growth rate
when people's awareness of health is enhanced and their
disposable income is increased.  This is the third product
of Sinovac. Our sales team is encouraged. And they are
confident to successfully bring this product to the Chinese
market. " 

    About Sinovac 

    Sinovac Biotech Ltd. is a China-based biopharmaceutical
company that focuses on the research, development,
manufacture and commercialization of vaccines that protect
against human infectious diseases. Sinovac's vaccines
include Healive(TM) (hepatitis A), Bilive(TM) (combined
hepatitis A and B) and Anflu(TM) (influenza).  Sinovac is
currently developing human vaccines against the H5N1 strain
of pandemic influenza, Japanese encephalitis and SARS. 

    Additional information about Sinovac is available on
its website, http://www.sinovac.com .  To be added to our
distribution list, please email: [e-mail] . 

    Safe Harbor Statement 

    This announcement contains forward-looking statements.
These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995.  These forward-looking statements can be
identified by words or phrases such as "will,"
"expects," "anticipates,"
"future," "intends," "plans,"
"believes," "estimates" and similar
statements. Among other things, the business outlook and
quotations from management in this press release contain
forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's
beliefs and expectations, are forward-looking statements. 
Forward-looking statements involve inherent risks and
uncertainties.  A number of important factors could cause
actual results to differ materially from those contained in
any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement,
except as required under applicable law. 

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   [phone] x871
     Fax:   [phone]
     Email: [e-mail] 

SOURCE  Sinovac Biotech Ltd.